Tasse Daniel 4

What Happened

• Daniel Tasse, a member of REGENXBIO’s board of directors, received equity awards on May 29, 2026: 9,807 shares reported as a restricted stock unit (RSU) award and 46,600 shares reported as a derivative (option-based) award. Both were reported with an acquisition price of $0.00 on the Form 4 (i.e., they were grants/awards, not open-market purchases or sales).

Key Details

• Transaction date: 2026-05-29; Filing date (Form 4): 2026-06-02 (timely filed).
• Reported price: $0.00 for both awards (standard reporting for grants; the filing does not state a cash value).
• Vesting: F1—9,807 RSU shares vest 100% on May 29, 2027 subject to continued service. F2—the derivative/option award vests on May 29, 2027 subject to continued service.
• Shares owned after the transaction: not specified in the filing.
• No sale, purchase, or cashless exercise reported; these are compensation grants (not a disposition).

Context

• These are time‑based awards that will only convert into owned shares if the director continues service through the stated vesting date (May 29, 2027). Such grants are common part of director compensation and do not by themselves indicate insider buying or selling sentiment.